Defunct Company
Total Trials
22
As Lead Sponsor
11
As Collaborator
Total Enrollment
5,642
NCT02627703
(Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer
Phase: N/A
Role: Collaborator
Start: May 31, 2010
Completion: Not specified
NCT01446185
Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients
Role: Lead Sponsor
Start: Jan 31, 2011
Completion: May 31, 2012
NCT01479894
Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients With Colon Cancer
Start: Nov 30, 2011
Completion: Jan 31, 2015
NCT03502213
Study In Urology Practices Looking At Impact Of OncotypeDX GPS Test On Men Choosing And Remaining On Active Surveillance
Start: Jul 1, 2014
Completion: Jun 30, 2018
NCT02347449
The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population
Start: Oct 31, 2014
Completion: Sep 30, 2016
NCT02969109
Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
Start: Oct 31, 2015
Completion: Sep 18, 2018
NCT02762877
Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer
Start: Apr 30, 2016
Completion: Jun 19, 2019
NCT02668276
Engaging Newly Diagnosed Men About Cancer Treatment Options
Completion: Aug 31, 2019
NCT02476786
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Phase: Phase 2
Start: Jan 17, 2017
Completion: Jul 31, 2032
NCT05549570
Comparative Bioavailability Study of Metformin/Sitagliptin 850 mg/50 mg Tablets in Healthy Male and Female Volunteers
Phase: Phase 1
Start: Oct 22, 2017
Completion: Nov 1, 2017
NCT03447132
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant
Phase: Phase 3
Start: Dec 20, 2017
Completion: Jul 20, 2021
NCT03256630
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
Start: Jan 10, 2018
Completion: Feb 28, 2019
NCT06363812
Probability of OncotypeDx to Reallocate As Low or High Risk of Recurrence Breast Cancer Patients with Uncertain Biology
Start: Mar 8, 2018
Completion: Dec 31, 2024
NCT05549583
Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers
Start: Apr 15, 2018
Completion: Apr 25, 2018
NCT03628066
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
Start: Oct 22, 2018
Completion: Jan 30, 2021
NCT03790813
Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers
Start: Jan 7, 2019
Completion: Dec 31, 2023
NCT04055493
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
Start: Jul 2, 2019
Completion: Jul 31, 2027
NCT04565054
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
Start: Sep 2, 2020
Completion: Jul 31, 2029
NCT06124560
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
Start: Oct 28, 2022
Completion: Nov 7, 2022
NCT06124573
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.
Start: Nov 7, 2022
Completion: Nov 21, 2022
NCT06124495
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
Start: Jan 13, 2023
Completion: Feb 13, 2023
NCT06124547
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.
Start: Jan 16, 2023